: In May 2019, the company’s molecular division, Primerdesign , launched the genesig® q32 qPCR instrument. This next-generation tool was a critical "update" to their hardware lineup, designed to provide faster PCR cycle times.
: Internal database records or software updates for their diagnostic instruments (like the genesig® series).
: During this window, Novacyt was in the process of selling non-core assets, such as its NOVAprep unit and clinical laboratory business, to focus on molecular testing. novacyy 20190526 sd upd
The period following May 2019 marked a radical shift for the company. By January 2020, Novacyt became a household name in the biotech sector by launching one of the first molecular tests for . Half Year Results | Novacyt
: On April 30, 2019, the company reported its 2018 results, noting narrowed losses and a focus on double-digit revenue growth. Decoding "SD UPD" : In May 2019, the company’s molecular division,
In early 2019, Novacyt was in a transitional phase. The company was actively streamlining its operations to focus on its high-growth diagnostic products, particularly through its and Lab21 brands.
While "SD UPD" is often technical shorthand, in the context of Novacyt’s 2019 operations, it may refer to: : During this window, Novacyt was in the
: Interestingly, Novacyt later acquired Southern Cross Diagnostics (SCD). While that acquisition occurred more recently (early 2026), the initials "SD" frequently appear in their internal supply chain and distribution documentation. The Evolution of Novacyt Post-2019
